Cocrystal Pharma

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alto Ingredients

Eyenovia

Hall of Fame Resort & Entertainment

Scopus BioPharma

5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Best Penny Stocks To Buy Right Now According To Insiders

Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Cocrystal Pharma, Inc. (COCP) Reports Q2 Loss, Misses Revenue Estimates

Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Cocrystal Pharma, Inc. (COCP) Report Negative Q2 Earnings? What You Should Know

Cocrystal Pharma Inc (NASDAQ: COCP) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.  "Our next steps are to scale-up synthesis and manufacture active pharmaceutical ingredient (API) to support Investigational New Drug (IND)-enabling studies to advance CDI-45205 into clinical trials," said James Martin, CFO, and interim co-CEO.

Cocrystal Pharma Stock Is Trading Higher After COVID-19 Candidate Shows Preclinical Activity Against Delta, Gamma Variants

The stock price of Cocrystal Pharma Inc (NASDAQ: COCP) increased by over 15% pre-market. This is why it happened.

COCP Stock Increases Over 15% Pre-Market: Why It Happened

Clear Channel Outdoor Holdings

1847 GOEDEKER INC.

Greenpro Capital Corp

OPKO Health

Regulus Therapeutics

Transocean

Staffing 360 Solutions

With July in full swing, here's 8 penny stocks that investors are watching right now The post 8 Hot Penny Stocks That You Should Add to Your July Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 Hot Penny Stocks That You Should Add to Your July Watchlist

BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces that it will be added to the Russell Microcap® Index after the U.S. market opens today, June 28, 2021.

Cocrystal Joins Russell Microcap® Index

BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1 clinical development of CC-42344 in the third quarter of 2021.

Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

Amarin Corporation Plc

Elite Education Group International Ltd

Luokung Technology Corp

Meten Holding Group Ltd.

NovaBay Pharmaceuticals

Which penny stocks are worth buying next month? Check these 7 out for your watchlist The post 7 Hot Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks to Watch That Are Trending Right Now

Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.

Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19

Cocrystal Pharma Inc (NASDAQ: COCP) has announced laboratory-based results for its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205. A third-party laboratory contracted by Cocrystal conducted in vitro studies evaluating the antiviral activity of CDI-45205 and its analogs in VeroE6-eGFP cells infected with SARS-CoV-2 (Wuhan strain), the U.K. variant (B.1.1.7), and the South African variant (B.1.351).

Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains

The stock price of Cocrystal Pharma Inc (NASDAQ: COCP) increased by over 10% pre-market. These are the details.

COCP Stock Price: Over 10% Increase Pre-Market Explanation

BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces that its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2 and two prominent SARS-CoV-2 variants.

Cocrystal's Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management's participation in the Noble Capital Markets C-Suite Interview Series is now available online. During the 30-minute video int e rview hosted by Noble Capital Markets Senior Equity Research Analyst Robert LeBoyer, Cocrystal discussed its antiviral drug-discovery and development work and provided program updates.

Cocrystal Pharma's Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online

A buying opportunity is here as COCP stock is down, even as Cocrystal makes progress in developing a potentially lifesaving antiviral drug. The post Target Highly Promising Antiviral Therapeutics with Cocrystal Pharma appeared first on InvestorPlace.

Target Highly Promising Antiviral Therapeutics with Cocrystal Pharma

Agenus

Atossa Genetics

Avid Bioservices

Ocugen, Inc.

SIGA Technologies

Sio Gene Therapies

Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appeared first on InvestorPlace.

7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts

BOTHELL, Wash., May 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, today announced the closing of its previously announced public offering of 26,000,000 shares of common stock of the Company, at a price to the public of $1.54 per share, less underwriting discounts and commissions.

Cocrystal Pharma Announces Closing of $40 Million Bought Deal

iBio

Nemaura Medical

Nemaura Medical Inc. (NASDAQ: NMRD), iBio, Inc. (NYSE: IBIO) and Cocrystal Pharma, Inc. (NASDAQ: COCP) are among the healthcare movers Wednesday. Nemaura Rallies On Receipt of Orders: Nemaura, a medtech company developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced the receipt of purchase orders for 5,000 sugarBEAT transmitters and 200,000 sugarBEAT sensors from its U.K. licensee DB Ethitronix.

Why Nemaura, iBio And Cocrystal Are Moving Wednesday

The trading in biotechnology company Cocrystal Pharma, Inc. (NASDAQ: COCP) is a good example of how inexperienced traders can lose a lot of money. What Happened: Cocrystal closed Tuesday at $2.14, a gain of over 70%.

Rookie Traders Get Crushed By Cocrystal Pharma Stock

Shares of Cocrystal Pharma Inc. plunged 28.3% in active premarket trading, after the biotechnology company announced a $40 million common stock offering. The company announced the offering Tuesday's closing bell, after the stock rocketed 72.6% on Tuesday after the announcement that "progress" was made in the development of the company's antiviral drug candidates targeting coronaviruses including those that cause COVID-19.

Cocrystal stock pulls back sharply after stock offering priced to the public at a deep discount

The stock price of Cocrystal Pharma Inc (NASDAQ: COCP) fell from $2.14 to $1.54 (down 28.04%) pre-market. This is why it happened.

COCP Stock: From $2.14 To $1.54 (28.04% Decrease) Pre-Market Explanation

Cocrystal Pharma Inc (NASDAQ: COCP) has entered into an underwriting agreement with H.C. Wainwright & Co LLC, under which the underwriter has agreed to purchase 26 million shares at $1.54 per share.

Cocrystal Pharma Shares Plunge On $40M Equity Raise At 28% Discount

BOTHELL, Wash., May 04, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 26,000,000 shares of common stock of the Company, at a price to the public of $1.54 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about May 7, 2021, subject to satisfaction of customary closing conditions.

Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock

Shares of Cocrystal Pharma Inc. more than doubled on massive record volume in afternoon trading Tuesday, a day after the biotechnology company said it has made "progress" in developing antiviral drug candidates that target coronaviruses, including those that cause COVID-19. Trading volume skyrocketed to 559.5 million shares, compared with the full-day average of about 832,300 shares.

Cocrystal stock doubles on massive volume a day after progress announced on coronavirus drug candidates

Bioline RX

Chemocentryx

Cocrystal Pharma, Inc. (NASDAQ: COCP), ChemoCentryx, Inc. (NASDAQ: CCXI), Neuronetics, Inc. (NASDAQ: STIM) and BioLineRx Ltd. (NASDAQ: BLRX) are among the biggest health care movers Tuesday.

Why Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving Today

News for Cocrystal Pharma Stock (COCP)